Lonza Group AG Stock Deutsche Boerse AG

Equities

LO3A

US54338V1017

Biotechnology & Medical Research

Market Closed - Deutsche Boerse AG 02:05:17 2024-07-12 am EDT 5-day change 1st Jan Change
53 EUR -0.93% Intraday chart for Lonza Group AG +7.29% +42.47%

Financials

Sales 2024 * 6.65B 7.44B 6.82B Sales 2025 * 7.63B 8.53B 7.82B Capitalization 37.41B 41.81B 38.33B
Net income 2024 * 873M 976M 894M Net income 2025 * 1.1B 1.23B 1.12B EV / Sales 2024 * 6.03 x
Net Debt 2024 * 2.73B 3.06B 2.8B Net Debt 2025 * 3.27B 3.65B 3.35B EV / Sales 2025 * 5.33 x
P/E ratio 2024 *
42.6 x
P/E ratio 2025 *
34 x
Employees 18,000
Yield 2024 *
0.87%
Yield 2025 *
1.01%
Free-Float 96.69%
More Fundamentals * Assessed data
Dynamic Chart
1 day-0.93%
1 week+7.29%
Current month+4.95%
1 month+4.95%
3 months-4.50%
6 months+34.52%
Current year+42.47%
More quotes
1 week
51.50
Extreme 51.5
53.50
1 month
49.40
Extreme 49.4
53.50
Current year
36.40
Extreme 36.4
56.50
1 year
32.00
Extreme 32
57.00
3 years
32.00
Extreme 32
61.00
5 years
32.00
Extreme 32
61.00
10 years
32.00
Extreme 32
61.00
More quotes
Managers TitleAgeSince
Director of Finance/CFO 52 21-11-30
Chief Operating Officer 55 22-07-31
Investor Relations Contact - -
Members of the board TitleAgeSince
Director/Board Member 64 14-04-15
Director/Board Member 66 14-04-15
Director/Board Member 58 22-05-04
More insiders
Date Price Change Volume
24-07-12 53 -0.93% 0
24-07-11 53.5 +3.88% 280
24-07-10 51.5 0.00% 0
24-07-09 51.5 0.00% 0
24-07-08 51.5 +4.25% 0

Delayed Quote Deutsche Boerse AG, July 12, 2024 at 02:05 am EDT

More quotes
Lonza Group AG is one of the world leaders of the development, production and marketing of chemical products. Net sales break down by family of products and services as follows: - bio-pharmaceuticals (55.4%): exclusive syntheses, microbiological fermentation products , mammalian cell cultures, etc.; - capsules and dosing solutions for biopharmaceuticals, drugs and nutrition products (17.3%). In addition, the group offers nutritional ingredients; - small molecule drug substances (13.4%); - technologies and platforms for manufacturing processes and production of cell and gene therapies (10.4%); - other (3.5%). Net sales are distributed geographically as follows: Switzerland (17.4%), Europe (31.7%), the United States (31.8%), the Americas (3.2%), Japan (8.1%), Asia (7.5%) and other (0.3%).
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
22
Last Close Price
518 CHF
Average target price
586 CHF
Spread / Average Target
+13.13%
Consensus